Peter J. McHugh

Peter J. McHugh

Auto-generated profile, based on publicly available information

Peter J. McHugh

Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2001 in The Lancet Oncology
Verified
Journal Article
Closed access
PMPeter J McHugh
Peter J McHugh
VSVictoria J Spanswick
Victoria J Spanswick
JHJohn A Hartley
John A Hartley

25 March 2021 in Nature
Verified
Journal Article
Closed access
PDF file
WWWei Wu
Wei Wu
SKSarah E. Kargbo-Hill
Sarah E. Kargbo-Hill
WNWilliam J. Nathan
William J. Nathan
JPJacob Paiano
Jacob Paiano
ECElsa Callen
Elsa Callen
ANAndré Nussenzweig
André Nussenzweig

15 February 2017 in Genes & Development
Verified
Journal Article
Open access
PDF file
EEErkin Erdal
Erkin Erdal
SHSyed Haider
Syed Haider
JRJan Rehwinkel
Jan Rehwinkel
DFDavid Favara
David Favara
PMPeter J. McHugh
Peter J. McHugh
Radiotherapy and chemotherapy are effective treatment methods for many types of cancer, but resistance is common. Recent findings indicate that antiviral type I interferon (IFN) signaling is induced by these treatments. However, the underlying mechanisms still need to be elucidated. Expression of a set of IFN-stimulated genes comprises an IFN-related DNA damage resistance signature (IRDS), which correlates strongly with resistance to radiotherapy and chemotherapy across different tumors. Classically, during viral infection, the presence of foreign DNA in the cytoplasm of host cells can initiate type I IFN signaling. Here, we demonstrate that DNA-damaging modalities used during cancer therapy lead to the release of ssDNA fragments from the cell nucleus into the cytosol, engaging this innate immune response. We found that the factors that control DNA end resection during double-strand break repair, including the Bloom syndrome (BLM) helicase and exonuclease 1 (EXO1), play a major role in generating these DNA fragments and that the cytoplasmic 3′–5′ exonuclease Trex1 is required for their degradation. Analysis of mRNA expression profiles in breast tumors demonstrates that those with lower Trex1 and higher BLM and EXO1 expression levels are associated with poor prognosis. Targeting BLM and EXO1 could therefore represent a novel approach for circumventing the IRDS produced in response to cancer therapeutics.

30 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
NWNiek van Wietmarschen
Niek van Wietmarschen
SSSriram Sridharan
Sriram Sridharan
WNWilliam J. Nathan
William J. Nathan
ATAnthony Tubbs
Anthony Tubbs
ECEdmond M. Chan
Edmond M. Chan
ANAndré Nussenzweig
André Nussenzweig

1 January 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JBJurgen Brem
Jurgen Brem
SBSander S. van Berkel
Sander S. van Berkel
DZDavid Zollman
David Zollman
SLSook Y. Lee
Sook Y. Lee
OGOpher Gileadi
Opher Gileadi
CSChristopher J. Schofield
Christopher J. Schofield
β-Lactams are the most successful antibacterials, but their effectiveness is threatened by resistance, most importantly by production of serine- and metallo-β-lactamases (MBLs). MBLs are of increasing concern because they catalyze the hydrolysis of almost all β-lactam antibiotics, including recent-generation carbapenems. Clinically useful serine-β-lactamase inhibitors have been developed, but such inhibitors are not available for MBLs. l -Captopril, which is used to treat hypertension via angiotensin-converting enzyme inhibition, has been reported to inhibit MBLs by chelating the active site zinc ions via its thiol(ate). We report systematic studies on B1 MBL inhibition by all four captopril stereoisomers. High-resolution crystal structures of three MBLs (IMP-1, BcII, and VIM-2) in complex with either the l - or d -captopril stereoisomer reveal correlations between the binding mode and inhibition potency. The results will be useful in the design of MBL inhibitors with the breadth of selectivity required for clinical application against carbapenem-resistant Enterobacteriaceae and other organisms causing MBL-mediated resistant infections.

1 January 2013 in Chemistry & Biology
Verified
Journal Article
Closed access
GNGiang Huong Nguyen
Giang Huong Nguyen
TDThomas S. Dexheimer
Thomas S. Dexheimer
ARAndrew S. Rosenthal
Andrew S. Rosenthal
Wai Kit ChuWai Kit Chu
Wai Kit Chu
DSDharmendra Kumar Singh
Dharmendra Kumar Singh
IHIan D. Hickson
Ian D. Hickson